2-Amino-3,4-dihydroquinazolines as Inhibitors of BACE-1 (β-Site APP Cleaving Enzyme): Use of Structure Based Design to Convert a Micromolar Hit into a Nanomolar Lead
Journal of Medicinal Chemistry2007Vol. 50(18), pp. 4261–4264
Citations Over TimeTop 10% of 2007 papers
Ellen W. Baxter, Kelly A. Conway, Ludo Kennis, François Bischoff, Marc Mercken, Hans De Winter, Charles H. Reynolds, Brett A. Tounge, Chi Luo, Malcolm K. Scott, Yifang Huang, Mirielle Braeken, Serge Pieters, Didier Berthelot, Stefan Masure, Wouter Bruinzeel, Alfonzo D. Jordan, Michael H. Parker, Robert E. Boyd, Junya Qu, Richard Alexander, Douglas E. Brenneman, Allen B. Reitz
Abstract
A new aspartic protease inhibitory chemotype bearing a 2-amino-3,4-dihydroquinazoline ring was identified by high-throughput screening for the inhibition of BACE-1. X-ray crystallography revealed that the exocyclic amino group participated in a hydrogen bonding array with the two catalytic aspartic acids of BACE-1 (Asp(32), Asp(228)). BACE-1 inhibitory potency was increased (0.9 microM to 11 nM K(i)) by substitution into the unoccupied S(1)' pocket.
Related Papers
- → Design, synthesis, biological evaluation, and molecular modeling studies of pyrazole-benzofuran hybrids as new α-glucosidase inhibitor(2021)33 cited
- → Structure activity relationship and optimization of N-(3-(2-aminothiazol-4-yl)aryl)benzenesulfonamides as anti-cancer compounds against sensitive and resistant cells(2017)15 cited
- → Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach(2009)20 cited
- → Synthesis and SAR studies of a novel class of S1P1 receptor antagonists(2007)14 cited
- → L-Aspartic acid monohydrate(2003)14 cited